Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520273 · ClinicalTrials.gov registry record · NA
A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA
A NA study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
- 100,000
- Enrollment target
NCT00520273 is a NA study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 100,000 participants.
The verdict
NCT00520273, a NA study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
- 100,000 participants
- Enrollment target
Study Summary
This study will evaluate the specificity of the cobas TaqScreen MPX Test for the simultaneous detection of HBV DNA, HCV RNA and HIV-1 Group M in a minimum of 100,000 individual donor samples in 96-unit pools.
Interventions
- DEVICE cobas s 201 TaqScreen MPX Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520273
The ClinicalTrials.gov registry entry for NCT00520273 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cobas s 201 TaqScreen MPX Test is the first listed.
NCT00520273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00520273 about?
NCT00520273 is a clinical study titled "A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA". This study will evaluate the specificity of the cobas TaqScreen MPX Test for the simultaneous detection of HBV DNA, HCV RNA and HIV-1 Group M in a minimum of 100,000 individual donor samples in 96-unit pools.
What is the current status of trial NCT00520273?
This trial is currently completed. It is a NA study. The enrollment target is 100,000 participants. The study started on 2007-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00520273?
The interventions under investigation include: cobas s 201 TaqScreen MPX Test (DEVICE).
Who is sponsoring clinical trial NCT00520273?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.